Asana BioSciences acquires drug discovery platform from Endo Pharmaceuticals

BRIDGEWATER, N.J. — Asana BioSciences, a research and development company specializing in the discovery and development of new chemical and biological entities, on Tuesday announced that it has acquired an early stage branded pharmaceutical discovery platform from Endo Pharmaceuticals. Asana's portfolio is comprised of multiple compounds for oncology and pain indications that are ready to enter clinical trials, the company said.



Asana is based in Bridgewater, N.J., and is led by Dr. Sandeep Gupta, CEO, who recently served as SVP of discovery and early development at Endo Pharmaceuticals.



“Asana’s mission is to develop novel and clinically differentiated products that address unmet clinical needs and provide new treatment options to physicians and patients," Gupta said. "Our team consists of highly experienced scientists who have successfully executed several drug discovery and clinical development projects. I am very excited about this portfolio and am looking forward to initiating our First-in-Man trials for our lead asset and moving other assets into clinical development.”



Asana is an independent member of the Amneal Alliance of Companies, which is made up of independent companies that focus on various disciplines within the life sciences. Other members include Amneal Pharmaceuticals, Therapeutic Proteins International, Kashiv Pharma and Prolong Pharmaceuticals.